We tested whether SV119 (an apoptogenic sigma-2 ligand) and a standard chemotherapeutic would slow tumor growth, reduce toxicity, and ultimately improve survival in a murine model of established pancreas adenocarcinoma. This evidence concerns the gene AP2S1 and neoplasm.